Studies inflating antidepressant efficacy?

Yesterday we reported on an article published in the New England Journal of Medicine that found studies with positive results were far more likely to be published than those with negative results. The study found that the FDA is working with raw data, whereas medical journals are not, which can contribute to misleading results about the efficacy of certain drugs, particularly antidepressants. And the folks over at the blog Clinical Psychology and Psychiatry have an in-dept look at exactly which antidepressants may have inflated benefits due to data suppression. The list includes Wellbutrin, Celexa, Cymbalta, Lexapro, Prozac, Remeron, Serzone, Paxil, Zoloft, and Effexor--every antidepressant approved between 1987 and 2004.

- see this blog entry for more

Suggested Articles

Levo Therapeutics’ lead program did not beat placebo in a phase 3 study of Prader-Willi syndrome, a genetic disorder that causes insatiable hunger.

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.